Business · 17/06/2024Updated: 10/17/2026 · 1 min read

FDA Announces Final Guidance for Diabetic Foot Infections Treatment Drugs

Summary

The FDA has released a final guidance document to help pharmaceutical companies develop effective treatments for diabetic foot infections, replacing a previous draft guidance issued in October 2023.

Original source language: Federal Register — Food and Drug AdministrationOpen original release →

Add your company to Business Communicator

We monitor business sources and connect attention with companies, profiles and services available in Business Communicator.

Create a free company profile Explore businesses on Business Maps →

Create a free company profile →

Explore insights

Business insights →

Healthcare Business News Global Markets News Trade Regulation News Business Technology News Fintech for Business: Payments & Banking News Supply Chain News

Related business signals

Business · 9/16/2026

Microbiology Devices Panel of the Medical Devices Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Pathogen-Agnostic Sequencing

The Food and Drug Administration (FDA) announces a public advisory committee meeting of the Microbiology Devices Panel to discuss pathogen-agnostic sequencing for emergency preparedness and response efforts.

Read summary →

Business · 9/16/2026

NIH Proposed Collection; 60-Day Comment Request; NIH Intramural Reporting of Research Misconduct (IRRM) Web Form

The National Institutes of Health (NIH) is proposing a web-based reporting form to help the Agency Intramural Research Integrity Officer (AIRIO) assess concerns and determine appropriate next steps in evaluating allegations of research misconduct.

Read summary →

Business · 9/16/2026

Food and Drug Administration Announces Proposed Collection of Information for Reporting of Biological Product Deviations and Human Cells, Tissues, and Cellular and Tissue-Based Product Deviations in Manufacturing

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

Read summary →

Business · 9/16/2026

Medicare Program; Medicare Appeals; Adjustment to the Amount in Controversy Threshold Amounts for Calendar Year 2027

The Medicare appeals process will adjust its amount in controversy threshold amounts for ALJ hearings and judicial review, effective January 1, 2027, with new thresholds of $200 for ALJ hearings and $2,000 for judicial review.

Read summary →

Business · 9/15/2026

National Cancer Institute Announces Closed Meeting

The National Cancer Institute has issued a notice regarding a closed meeting, which is not open to the public.

Read summary →

Business · 9/15/2026

National Cancer Institute Considers Exclusive Patent License for Engineered Cell Therapies for HPV 16 E6-Expressing Cancers

The National Cancer Institute, part of the National Institutes of Health, Department of Health and Human Services, is considering granting an exclusive patent license to MedGene Therapeutics, Inc., a Maryland-based company, to develop and commercialize engineered cell therapies for treating cancers caused by the HPV 16 E6 gene.

Read summary →